← Back to screener

Oric Pharmaceuticals, Inc. ORIC

Rank #2175 · Nasdaq · $1.0B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
30.5
P/E
-7.5
P/B
4.27
ROE
-57.1%
Op. Margin
–%
Debt Ratio
14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -7.5x, P/B 4.27x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -57.1%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 14%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–$-0.0B$-0.0B$-0.0B–-14
2021–$-0.0B$-0.0B$-0.1B–-14
2022–$-0.1B$-0.1B$0.3B–9
2023–$-0.1B$-0.1B$0.3B–9
2024–$-0.1B$-0.1B$0.2B–13
2025–$-0.1B$-0.1B$0.2B–14

← See the full screener